In accordance, many TLRs agonists (imiquimod for TLR7 and CpG for TLR9) or cGAS-STING triggers were employed to activate anti-viral interferon-mediated immune responses with final aim to polarise myeloid cells towards an anti-tumour state, prime, and support T cell-mediated anti-tumour immunity [204, 205]. Here, TLR9 is linked to neoplasm.